Wetzel Investment Advisors Inc. Sells 122 Shares of Johnson & Johnson $JNJ

Wetzel Investment Advisors Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 2.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,187 shares of the company’s stock after selling 122 shares during the quarter. Wetzel Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $640,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Highline Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the first quarter worth about $52,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. UBS Group lifted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Price Performance

Shares of JNJ opened at $185.99 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a 50 day simple moving average of $175.45 and a 200 day simple moving average of $162.51. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $186.56. The firm has a market capitalization of $447.92 billion, a PE ratio of 19.89, a P/E/G ratio of 2.36 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 55.61%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.